Nanobiotix Closes $100M Global Offering, Extends Cash Runway Into 2029
Summary
Nanobiotix announced the closing of its global offering, raising approximately $100 million in gross proceeds, including the full exercise of the underwriters' option. This follows the pricing announcement on May 21st, which indicated $98.6 million. The successful completion of this capital raise is significant for the company, providing sufficient funds to meet working capital requirements and extend its operational runway into 2029. For a clinical-stage biotechnology company, securing funding for several years is critical for advancing its pipeline.
At the time of this announcement, NBTX was trading at $40.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $3.64 to $57.14. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.